This study characterized tumor-reactive T cells in the bone marrow of patients with multiple myeloma (MM) and acute myeloid leukemia (AML) using integrated TCR profiling, HLA immunopeptidomics, and functional screening, with the goal of understanding their transcriptional identity and clinical relevance to immunotherapy response.
Tumor-reactive bone marrow T cells display a conserved effector program distinct from exhaustion seen in solid tumors; a transcriptional classifier (TFiT) built on this program stratified immunotherapy—but not chemotherapy—response across independent MM and AML cohorts, supporting specificity for T cell-mediated tumor control.
Full text was not accessible; findings are based solely on the abstract. Sample sizes, cohort demographics, and granular statistical outcomes are not reported here. The classifier's generalizability beyond MM and AML has not been tested.
A latent but activatable anti-tumor T cell compartment exists in bone marrow malignancies—the TFiT classifier may help identify MM and AML patients most likely to benefit from immunotherapy rather than chemotherapy. Clinicians should watch for prospective validation studies of TFiT as a predictive biomarker.
